RCUS FY 2021 Earnings — Arcus Biosciences, Inc. Revenue & Financial Results | Market Cap Arena

RCUSArcus Biosciences, Inc.

$2B

FY 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$383M+391.0% YoY

Gross Profit

$383M100.0% margin

Operating Income

$54M14.1% margin

Net Income

$53M13.8% margin

EPS (Diluted)

$0.71

Cash Flow

Operating Cash Flow

-$256M

Free Cash Flow

-$282M

Stock-Based Comp.

$55M

Balance Sheet

Total Assets

$1.6B

Total Liabilities

$750M

Stockholders' Equity

$841M

Cash & Equivalents

$148M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$383M	$78M	+391.0%
Gross Profit	$383M	$78M	+391.0%
Operating Income	$54M	-$124M	+143.5%
Net Income	$53M	-$123M	+143.1%